{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:38:46Z","timestamp":1791754726915,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Li-Fraumeni syndrome (LFS) is an autosomal dominant hereditary cancer syndrome caused by pathogenic variants in the gene <jats:italic>TP53<\/jats:italic>. This gene codes for the P53 protein, a crucial player in genomic stability, which functions as a tumor suppressor gene. Individuals with LFS frequently develop multiple primary tumors at a young age, such as soft tissue sarcomas, breast cancer, and brain tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 38 years-old female with a history of femur osteosarcoma, ductal carcinoma of the breast, high-grade breast sarcoma, pleomorphic sarcoma of the left upper limb, infiltrating lobular carcinoma of the breast, gastric adenocarcinoma, leiomyosarcoma of the right upper limb, and high-grade pleomorphic renal sarcoma. Complete molecular sequencing of the <jats:italic>TP53<\/jats:italic> gene showed c.586\u00a0C\u2009&gt;\u2009T (p.R196X) in exon 6, which is a nonsense mutation that produces a shorter and malfunctioning P53. Family history includes advanced father\u2019s age at the time of conception (75 years), which has been associated with an increased risk of de novo germline mutations. The patient had seven paternal half-siblings with no cancer history. The patient received multiple treatments including surgery, systemic therapy, and radiotherapy, but died at the age of 38.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Advanced paternal age is a risk factor to consider when hereditary cancer syndrome is suspected. Early detection of hereditary cancer syndromes and their multi-disciplinary surveillance and treatment is important to improve clinical outcomes for these patients. Further investigation of the relationship between the pathogenic variant of <jats:italic>TP53<\/jats:italic> and its phenotype may guide the stratification of surveillance and treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13053-023-00272-2","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T13:02:08Z","timestamp":1705582928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Li-Fraumeni syndrome presenting with de novo TP53 mutation, severe phenotype and advanced paternal age: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Juan Pablo","family":"Arango-Iba\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gabriel","family":"Parra-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela R.","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Ximena","family":"Rodr\u00edguez-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"issue":"6","key":"272_CR1","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1097\/AOG.0000000000003563","volume":"134","author":"Hereditary Cancer Syndromes and Risk Assessment","year":"2019","unstructured":"Hereditary Cancer Syndromes and Risk Assessment. Acog Committee Opinion Summary, number 793. Obstet Gynecol. 2019;134(6):1366\u20137. https:\/\/doi.org\/10.1097\/AOG.0000000000003563.","journal-title":"Obstet Gynecol"},{"issue":"18","key":"272_CR2","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJM199310283291807","volume":"329","author":"CC Harris","year":"1993","unstructured":"Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329(18):1318\u201327. https:\/\/doi.org\/10.1056\/NEJM199310283291807.","journal-title":"N Engl J Med"},{"key":"272_CR3","unstructured":"Schneider K, Zelley K, Nichols KE, Garber J et al. Li-Fraumeni Syndrome. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2022 Oct 16]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1311\/."},{"issue":"8","key":"272_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/nrg3241","volume":"13","author":"JA Veltman","year":"2012","unstructured":"Veltman JA, Brunner HG. De novo mutations in human genetic disease. Nat Rev Genet. 2012;13(8):565\u201375. https:\/\/doi.org\/10.1038\/nrg3241.","journal-title":"Nat Rev Genet"},{"issue":"21","key":"272_CR5","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni Syndrome from TP53 mutation carriers. J Clin Oncol off J Am Soc Clin Oncol. 2015;33(21):2345\u201352. https:\/\/doi.org\/10.1200\/JCO.2014.59.5728.","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"4","key":"272_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1947601911413466","volume":"2","author":"D Malkin","year":"2011","unstructured":"Malkin D, Li-Fraumeni S. Genes Cancer. 2011;2(4):475\u201384. https:\/\/doi.org\/10.1177\/1947601911413466.","journal-title":"Genes Cancer"},{"issue":"12","key":"272_CR7","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1054\/bjoc.2000.1167","volume":"82","author":"A Chompret","year":"2000","unstructured":"Chompret A, Brugi\u00e8res L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82(12):1932\u20137. https:\/\/doi.org\/10.1054\/bjoc.2000.1167.","journal-title":"Br J Cancer"},{"issue":"1","key":"272_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13059-016-1110-1","volume":"17","author":"R Acuna-Hidalgo","year":"2016","unstructured":"Acuna-Hidalgo R, Veltman JA, Hoischen A. New insights into the generation and role of de novo mutations in health and disease. Genome Biol. 2016;17(1):241. https:\/\/doi.org\/10.1186\/s13059-016-1110-1.","journal-title":"Genome Biol"},{"issue":"4","key":"272_CR9","doi-asserted-by":"publisher","first-page":"a026187","DOI":"10.1101\/cshperspect.a026187","volume":"7","author":"T Guha","year":"2017","unstructured":"Guha T, Malkin D. Inherited TP53 mutations and the Li-Fraumeni Syndrome. Cold Spring Harb Perspect Med. 2017;7(4):a026187. https:\/\/doi.org\/10.1101\/cshperspect.a026187.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"272_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/sj.onc.1202033","volume":"17","author":"JM Birch","year":"1998","unstructured":"Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998;17(9):1061\u20138. https:\/\/doi.org\/10.1038\/sj.onc.1202033.","journal-title":"Oncogene"},{"issue":"1","key":"272_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cancergencyto.2004.02.017","volume":"154","author":"I Bendig","year":"2004","unstructured":"Bendig I, Mohr N, Kramer F, Weber BHF. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and swiss origin. Cancer Genet Cytogenet. 2004;154(1):22\u20136. https:\/\/doi.org\/10.1016\/j.cancergencyto.2004.02.017.","journal-title":"Cancer Genet Cytogenet"},{"issue":"15","key":"272_CR12","first-page":"5718","volume":"61","author":"P Vahteristo","year":"2001","unstructured":"Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res. 2001;61(15):5718\u201322.","journal-title":"Cancer Res"},{"issue":"9","key":"272_CR13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295\u2013305. https:\/\/doi.org\/10.1016\/S1470-2045(16)30249-2.","journal-title":"Lancet Oncol"},{"issue":"11","key":"272_CR14","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1038\/s41436-019-0541-y","volume":"21","author":"HQ Rana","year":"2019","unstructured":"Rana HQ, Clifford J, Hoang L, LaDuca H, Black MH, Li S, et al. Genotype-phenotype associations among panel-based TP53\u2009+\u2009subjects. Genet Med off J Am Coll Med Genet. 2019;21(11):2478\u201384. https:\/\/doi.org\/10.1038\/s41436-019-0541-y.","journal-title":"Genet Med off J Am Coll Med Genet"},{"issue":"10","key":"272_CR15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG, European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet EJHG. 2020;28(10):1379\u201386. https:\/\/doi.org\/10.1038\/s41431-020-0638-4.","journal-title":"Eur J Hum Genet EJHG"},{"issue":"12","key":"272_CR16","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s10147-021-02011-w","volume":"26","author":"T Kumamoto","year":"2021","unstructured":"Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H, et al. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol. 2021;26(12):2161\u201378. https:\/\/doi.org\/10.1007\/s10147-021-02011-w.","journal-title":"Int J Clin Oncol"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-023-00272-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-023-00272-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-023-00272-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T13:12:46Z","timestamp":1705583566000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-023-00272-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["272"],"URL":"https:\/\/doi.org\/10.1186\/s13053-023-00272-2","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"authors declare no direct or indirect conflicts of interest. Informed consent from the patient was obtained for research purposes. This study was approved by the Comit\u00e9 de \u00c9tica en Investigaci\u00f3n Biom\u00e9dica of Fundaci\u00f3n Valle del Lili and is in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}